Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + Anti-PD-1 in Advanced NSCLC
NCT04059874Phase 1Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of donafenib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Safety assessments. Status: unknown.
02
Drugs
donafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04059874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04059874.